Scientists offer hope for genetically determined obesity

Image
IANS London
Last Updated : Jun 03 2018 | 10:50 AM IST

Unable to maintain weight loss due to your genetic predisposition to obesity? Take heart, an injectable drug widely used to lower blood sugar levels can help you fight overweight, suggest a study.

Around two to six per cent of all people with obesity develop obesity already in early childhood because they are genetically programmed to do so.

Obesity-causal mutations in one of their "appetite genes" gives them a strong genetic predisposition for developing obesity, also called monogenic obesity. Their experience of hunger is over-ruling and their feeling of satiety limited.

Researchers discovered that this group of people with obesity can lose weight with the help of the medicine liraglutide -- a modified form of the appetite-inhibiting hormone GLP-1 naturally secreted from the intestine when we eat.

"The appetite-inhibiting drug liraglutide has a positive effect on them. They feel less hungry and lose six per cent of their body weight within four months," said lead author Signe Sorensen Torekov, associate professor at the University of Copenhagen in Denmark.

In the study, published in the journal Cell Metabolism, the team have examined a small group with obesity caused by pathogenic mutations in the so-called MC4R gene and those with obesity without the mutations.

Both groups were treated with the medicine for four months; no changes were made to their diet and level of exercise in this period.

The individuals with this most common form of monogenic obesity lost 7 kg of their body weight compared to 6 kg for the people with common obesity.

Medicine acting as an analogue to our natural GLP-1 hormone is already available, as it has been approved by both the US Food Drug Association and European Medicines Agency for the treatment of obesity and Type 2 diabetes.

The study thus makes it possible to treat the most common form of genetically caused obesity, where patients respond poorly to existing treatments, the researchers noted.

As MC4R mutations cause obesity already in early childhood, the researchers hope the results can pave the way for new studies on young people in the future.

--IANS

rt/ksk

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 03 2018 | 10:38 AM IST

Next Story